Considering this, along with the presumed link between high RA disease activity and LPD [11] and the refractoriness to various DMARDs associated with anti-Ro/SS-A antibodies [27,30], the presence of anti-Ro/SS-A antibodies—even without a clinical diagnosis of SS—might be another important factor for rheumatologists to consider when choosing DMARDs. The gene discussed is RO60; the disease is synovial sarcoma.